GT-1 / Geom Therap - LARVOL DELTA

Novel drug candidates against antibiotic-resistant microorganisms: A review. (PubMed, Iran J Basic Med Sci) - "This review focuses on the resistance mechanisms of the top five threatening pathogens identified by the World Health Organization's global priority pathogens list: carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, carbapenem-resistant, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin, vancomycin-resistant Staphylococcus aureus...The novel drugs against carbapenem-resistant bacteria include LCB10-0200, apramycin, and eravacycline, while for Enterobacteriaceae, the drug candidates are LysSAP-26, DDS-04, SPR-206, nitroxoline, cefiderocol, and plazomicin. TNP-209, KBP-7072, and CRS3123 are agents against E. faecium, while Debio 1450, gepotidacin, delafloxacin, and dalbavancin are drugs against antibiotic-resistant S. aureus. In addition to these identified drug candidates, continued in vitro and in vivo studies are required to investigate small..."

Journal • Review

Antibacterial Activity of LCB10-0200 against Klebsiella pneumoniae. (PubMed, Antibiotics (Basel)) - "LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant K. pneumoniae strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by K. pneumoniae."

Journal • Infectious Disease • Nephrology • Pneumonia • Respiratory Diseases

In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea. (PubMed, Pharmaceuticals (Basel)) - "Minimal inhibitory concentrations (MICs) of LCB10-0200, LCB10-0200/AVI, aztreonam, aztreonam/AVI, ceftazidime, ceftazidime/AVI, and meropenem were measured using the agar dilution method. LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae."

Journal • Preclinical • Infectious Disease • Pneumonia

Pharmacokinetics-pharmacodynamics of the novel beta-lactamase inhibitor GT-055 in combination with the siderophore cephalosporin GT-1 (ECCMID 2019) - "When GT-055 is paired with the novel siderophore cephalosporin, GT-1 (formerly LCB10-0200), the BLI has been shown to improve the in vitro activity up to 8-fold against a variety of Gram-negative organisms including Enterobacteriaceae. Results of GT-1 + GT-055 in vitro studies provided insight about the activity of the inhibitor when utilized in combination with GT-1 and will serve to guide future studies."

Combination therapy • PK/PD data

In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains. (PubMed, Antibiotics (Basel)) - "This study investigates GT-1 (also known as LCB10-0200), a novel-siderophore cephalosporin, inhibited multidrug-resistant (MDR) Gram-negative pathogen, via a Trojan horse strategy exploiting iron-uptake systems...Compared with CAZ-AVI, GT-1/GT-055 exhibited lower MICs against E. coli and K. pneumoniae isolates. GT-1 demonstrated potent in vitro activity against clinical panel strains of E. coli, K. pneumoniae and Acinetobacter spp. GT-055 enhanced the in vitro activity of GT-1 against many GT-1-resistant strains."

Journal • Preclinical • Infectious Disease • Pneumonia • Respiratory Diseases